info@seagull-health.com
SeagullHealth
search
asfotase alfa(Strensiq)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Strensiq(asfotase alfa) Instructions:Uses,Dosage, Side Effects
STRENSIQ (asfotase alfa) is a recombinant human tissue-nonspecific alkaline phosphatase enzyme replacement therapy. It is formulated as a sterile, preservative-free, aqueous solution for subcutaneous injection.
This biologic agent is specifically designed to address the underlying metabolic deficiency in patients with hypophosphatasia (HPP), a rare genetic disorder characterized by defective bone mineralization.
STRENSIQ is indicated for the treatment of patients with perinatal/infantile-onset and juvenile-onset hypophosphatasia (HPP).
1. Perinatal/Infantile-Onset HPP:
6 mg/kg/week subcutaneously, either as 2 mg/kg three times per week or 1 mg/kg six times per week.
May be increased to 9 mg/kg/week (3 mg/kg three times per week) if response is inadequate.
2. Juvenile-Onset HPP:
6 mg/kg/week subcutaneously, as 2 mg/kg three times per week or 1 mg/kg six times per week.
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- haiousales@gmail.com
